[go: up one dir, main page]

GB2020665A - Acyl-N-acetylmuramylpeptide- antigen conjugate - Google Patents

Acyl-N-acetylmuramylpeptide- antigen conjugate

Info

Publication number
GB2020665A
GB2020665A GB7909795A GB7909795A GB2020665A GB 2020665 A GB2020665 A GB 2020665A GB 7909795 A GB7909795 A GB 7909795A GB 7909795 A GB7909795 A GB 7909795A GB 2020665 A GB2020665 A GB 2020665A
Authority
GB
United Kingdom
Prior art keywords
acyl
antigen
conjugate
group
acetylmuramylpeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB7909795A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of GB2020665A publication Critical patent/GB2020665A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • C07K9/005—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure containing within the molecule the substructure with m, n > 0 and m+n > 0, A, B, D, E being heteroatoms; X being a bond or a chain, e.g. muramylpeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

An acyl-N-acetylmuramyl peptide derivative-antigen conjugate, in which more than one of the hydroxyl groups in N-acetylglucosamine are substituted with acyl group, particularly with mycoloyl group to give the compound lipophilic property; and a di- or tripeptide is introduced as a spacer into the carboxyl group, thereby binding an antigen through its amino acid; and to a process for the preparation of said conjugate. On administration to an animal, the conjugate selectively suppresses the production of IgE antibody by an antigen later administered and thus may be applied for prevention or treatment of atopic disease without suppressing the normal immune response.
GB7909795A 1978-03-31 1979-03-20 Acyl-N-acetylmuramylpeptide- antigen conjugate Withdrawn GB2020665A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP3790178A JPS54130516A (en) 1978-03-31 1978-03-31 Acyllnnacetylmuramylpeptide derivativeeantigen combination

Publications (1)

Publication Number Publication Date
GB2020665A true GB2020665A (en) 1979-11-21

Family

ID=12510433

Family Applications (1)

Application Number Title Priority Date Filing Date
GB7909795A Withdrawn GB2020665A (en) 1978-03-31 1979-03-20 Acyl-N-acetylmuramylpeptide- antigen conjugate

Country Status (4)

Country Link
JP (1) JPS54130516A (en)
DE (1) DE2912865A1 (en)
FR (1) FR2421178A1 (en)
GB (1) GB2020665A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10610564B2 (en) 2015-02-26 2020-04-07 Stc.Unm IRGM and precision autophagy controls for antimicrobial and inflammatory disease states and methods of detection of autophagy
WO2020109792A1 (en) * 2018-11-28 2020-06-04 Pedanius Therapeutics Limited Antibacterial antisense agents

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2482959A2 (en) * 1979-06-29 1981-11-27 Rhone Poulenc Ind Merrifield synthesis of immunostimulant and adjuvant tri:peptide(s) - produces fatty acid acrylated l-alanine d-glutamic acid 2-lysine or 2,6-di:amino-pimelamic acid cpds.
FR2482958A2 (en) * 1979-06-29 1981-11-27 Rhone Poulenc Ind Immunostimulant and adjuvant L-alanyl-D-glutamyl tri:peptide derivs. - in which the C-terminal aminoacid is l-lysine or di:amino-pimelic acid and which has a fatty acid n-acyl gp.
DK156252C (en) * 1979-07-31 1989-12-18 Fujisawa Pharmaceutical Co METHOD OF ANALOGUE FOR THE PREPARATION OF DI, TRIAL OR TETRAPEPTIDE DERIVATIVES OR SALTS THEREOF
DE3070278D1 (en) * 1979-10-11 1985-04-18 Fujisawa Pharmaceutical Co Peptides, processes for their preparation and pharmaceutical compositions containing them
FR2477551A1 (en) * 1980-03-10 1981-09-11 Anvar NEW DERIVATIVES OF A-TREHALOSE AND MEDICAMENTS CONTAINING SAME
FR2546756B1 (en) * 1983-06-03 1985-11-29 Centre Nat Rech Scient NOVEL IMMUNOSTIMULATING DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS MEDICAMENTS
US4877795A (en) * 1987-01-30 1989-10-31 Kissei Pharmaceutical Co., Ltd. 4H-quinolizin-4-one compounds useful for the treatment of allergic bronchial asthma, allergic rhinitis atropic dermatitis and the like

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH453269A4 (en) * 1968-03-29 1973-01-31
US4186194A (en) * 1973-10-23 1980-01-29 Agence Nationale De Valorisation De La Recherche (Anvar) Water soluble agents effective as immunological adjuvants for stimulating, in the host the immune response to various antigens and compositions, notably vaccines containing said water soluble agents
FI66878C (en) * 1978-02-24 1984-12-10 Ciba Geigy Ag FOERFARANDE FOER FRAMSTAELLNING AV NYA ANTIGENDERIVAT

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10610564B2 (en) 2015-02-26 2020-04-07 Stc.Unm IRGM and precision autophagy controls for antimicrobial and inflammatory disease states and methods of detection of autophagy
WO2020109792A1 (en) * 2018-11-28 2020-06-04 Pedanius Therapeutics Limited Antibacterial antisense agents
GB2579253A (en) * 2018-11-28 2020-06-17 Pedanius Therapeutics Ltd Antibacterial antisense agents

Also Published As

Publication number Publication date
DE2912865A1 (en) 1979-10-18
FR2421178A1 (en) 1979-10-26
JPS54130516A (en) 1979-10-09

Similar Documents

Publication Publication Date Title
DE60103066T2 (en) CHLORELLA PREPARATIONS WITH IMMUNOMODULATIVE PROPERTIES
GB1257263A (en)
JPS5461112A (en) Oncostatic polysaccharide* its preparation* and oncostatic drugs containing it as an effective component
KR880000098A (en) Chondroitin Sulfate Immunostimulatory Composition
AU7933891A (en) Process for enhancing the resistance of aquatic animals to disease
EP0067130A3 (en) Capsules containing the active principle of an allergen, and process for their preparation
KR910002467A (en) Polyclonal immunoglobulin preparation for intravenous administration containing lgM and preparation method thereof
DE2331144A1 (en) WATER-SOLUBLE EXTRACTS FROM MYCOBACTERIA
JPS568320A (en) Drug for tumor immunotherapy comprising lipopolysaccharide as active constituent
GB2020665A (en) Acyl-N-acetylmuramylpeptide- antigen conjugate
Nikiforuk et al. Purification and properties of protein from embryonic bovine enamel
GB1395090A (en) Stabilized hormone compositions
Suzuki et al. Inhibition by Lipopolysaccharide (Endotoxin) of Antibody Response of Rabbit to Common Antigen of Enterobacteriaceae.
Schmidt et al. Immunodiffusion reactions with rubella antigens
Lopez-Merino et al. Immunization by an insoluble fraction extracted from Brucella melitensis: immunological and chemical characterization of the active substances
JPH05500817A (en) Immunostimulants based on polar glycopeptide lipids of Mycobacterium chelonae
GB1355961A (en) Preparation of immunosuppressive antilymphocytic serum
DE68917138D1 (en) TOLERANCE INDUCTION TO A FOREIGNANT.
BE790287A (en) PYRIMIDIN-6YL ACETHYDROXAMIC ACIDS, THEIR PREPARATION PROCESS AND THEIR THERAPEUTIC APPLICATION
Atkins et al. Studies on the structure and distribution of immunoglobulin A-containing cells in the gut of the pig
KR910700259A (en) How T-cell Recognized Peptide Modifications Influence the Immune Response
Rosan et al. Toxicity of Lactobacillus casei
Isenberg et al. Immunological and toxic differences between mouse-virulent and mouse-avirulent Candida albicans
Taniyama et al. Purification of polysaccharide antigen from Leptospira biflexa strain Urawa
Dalen et al. Antibodies against extractable components from Propionibacterium acnes in humans with and without acne vulgaris

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)